Comirnaty – Pandemic Timeline https://pandemictimeline.com Chronological Sequence of Events Fri, 07 Apr 2023 15:59:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.2 https://pandemictimeline.com/wp-content/uploads/2021/06/Covid-150x150.ico Comirnaty – Pandemic Timeline https://pandemictimeline.com 32 32 Graphene found in COVID-19 vaccine https://pandemictimeline.com/2021/06/graphene-found-in-covid-19-vaccine/ Mon, 14 Jun 2021 00:00:51 +0000 https://pandemictimeline.com/?p=1364 A Pfizer document mentioning graphene oxide was included in the February 2023 document dump. Whether the jabs contain graphene oxide is no longer speculation. We are no longer depending on laboratory science to show us that the jabs contain graphene oxide. This is now documented by Pfizer. Graphene oxide in the jabs is now an…

Read more →

]]>

Crystals seen in Comirnaty vaccine, from Jonathan Kleck video

A Pfizer document mentioning graphene oxide was included in the February 2023 document dump. Whether the jabs contain graphene oxide is no longer speculation. We are no longer depending on laboratory science to show us that the jabs contain graphene oxide. This is now documented by Pfizer. Graphene oxide in the jabs is now an indisputable fact.

Ricardo Delgado of La Quinta Columna sent a vial of the Comirnaty™ COVID-19 vaccine, which is the Pfizer brand in Europe, to Prof. Dr. Pablo Campra Madrid of Universidad de Almería, Spain, for analysis.

The findings showed that the detectable RNA is 6ng/ul and graphene oxide is  747 ng/ul. That makes the graphene oxide 99.2% and the RNA to be 0.8% of the vaccine by weight.

Graphene oxide acquires powerful magnetic properties inside the organism. This is the explanation for the magnetic phenomenon that billions of people around the world have already experienced after various routes of administration of graphene oxide. Among them the vaccine.

Graphene is an important material in the development of transhumanist technologies.

Robert Young and his team found some other elements in the vaccines as well.

There are plenty of studies of graphene as a vaccine adjuvant.  I have linked in several of them below in the “Related” section. However, when a material such as graphene has multiple uses, it is necessary to consider that an implementation may surreptitiously take advantage of another of the multiple uses or perhaps expose the product to be used in various ways, even when those uses are not explicitly cited as the reason for the use of the material in the product. Or, the other uses may not have been in the plan of the original implementers, but other parties may choose to take advantage of them. One link I found would make it seem to be the ideal material for transhumanism.

Sources:

Related:

  • Patent
    April 12, 2012. Ian Kinloch, Robert Young, Jonathan P. Rourke, and Neil R. Wilson. Graphene oxide. World Intellectual Property Organization WO2012046069A1, filed October 6, 2011, and issued April 12, 2012.
    https://patents.google.com/patent/WO2012046069A1/en.
    Patent.
  • Research Journal
    October 15, 2013. Chul Chung, Young-Kwan Kim, Dolly Shin, Soo-Ryoon Ryoo, Byung Hee Hong, and Dal-Hee Min. “Biomedical Applications of Graphene and Graphene Oxide.” Accounts of Chemical Research 46 (10): 2211–24.
    https://doi.org/10.1021/ar300159f.
    Research Journal.
    “Graphene has unique mechanical, electronic, and optical properties, which researchers have used to develop novel electronic materials including transparent conductors and ultrafast transistors.”
  • Blog
    July 14, 2021. “La Quinta Columna: Zinc Helps Raise Glutathione Levels and Glutathione Helps Degrade Graphene Oxide.” ORWELL CITY.
    https://www.orwell.city/2021/07/zinc-glutathione.html.
    Blog.
  • Research Journal
    May 11, 2021. Chunhong Dong, Ye Wang, Gilbert X. Gonzalez, Yao Ma, Yufeng Song, Shelly Wang, Sang-Moo Kang, Richard W. Compans, and Bao-Zhong Wang. “Intranasal Vaccination with Influenza HA/GO-PEI Nanoparticles Provides Immune Protection against Homo- and Heterologous Strains.” Proceedings of the National Academy of Sciences 118 (19).
    https://doi.org/10.1073/pnas.2024998118.
    Research Journal.
  • Video University
    April 14, 2016. Rice University. Nanotubes Assemble! Rice Introduces Teslaphoresis. Runtime: 2:54.
    https://www.youtube.com/watch?v=w1d0Lg6wuvc.
    Video, University.
    They are using graphene in these experiments.
  • Research Journal
    December 2020. A.K. Srivastava, N. Dwivedi, C. Dhand, R. Khan, N. Sathish, M.K. Gupta, R. Kumar, and S. Kumar. “Potential of Graphene-Based Materials to Combat COVID-19: Properties, Perspectives, and Prospects.” Materials Today. Chemistry 18 (December): 100385.
    https://doi.org/10.1016/j.mtchem.2020.100385.
    Research Journal.
  • Research Journal
    February 14, 2016. Ligeng Xu, Jian Xiang, Ye Liu, Jun Xu, Yinchan Luo, Liangzhu Feng, Zhuang Liu, and Rui Peng. “Functionalized Graphene Oxide Serves as a Novel Vaccine Nano-Adjuvant for Robust Stimulation of Cellular Immunity.” Nanoscale 8 (6): 3785–95.
    https://doi.org/10.1039/c5nr09208f.
    Research Journal.
  • Research Journal
    August 2020. Wanjun Cao, Lin He, Weidong Cao, Xiaobing Huang, Kun Jia, and Jingying Dai. “Recent Progress of Graphene Oxide as a Potential Vaccine Carrier and Adjuvant.” Acta Biomaterialia 112 (August): 14–28.
    https://doi.org/10.1016/j.actbio.2020.06.009.
    Research Journal.
  • Research Journal
    March 1, 2014. Xiaoqing Guo, and Nan Mei. “Assessment of the Toxic Potential of Graphene Family Nanomaterials.” Journal of Food and Drug Analysis, Nanomaterials – Toxicology and Medical Applications, 22 (1): 105–15.
    https://doi.org/10.1016/j.jfda.2014.01.009.
    Research Journal.
  • Patent
    January 15, 2021. 崔大祥, 高昂, 梁辉, 田静, 李雪玲, and 沈琦. 以氧化石墨烯为载体的纳米冠状病毒重组疫苗 (Nano coronavirus recombinant vaccine taking graphene oxide as carrier). China CN112220919A, filed September 27, 2020, and issued January 15, 2021.
    https://patents.google.com/patent/CN112220919A/en?q=graphene+oxide+vaccine&oq=graphene+oxide+vaccine.
    Patent.
  • Magazine Video
    July/August 2018. “Graphene Biointerface Optically Controls Heart Cells.” Photonics Media. Runtime of embedded video: 0:13.
    https://www.photonics.com/Articles/Graphene_Biointerface_Optically_Controls_Heart/a63489.
    Magazine, Video.
  • Research Journal
    May 1, 2018. Alex Savchenko, Volodymyr Cherkas, Chao Liu, Gary B. Braun, Alexander Kleschevnikov, Yury I. Miller, and Elena Molokanova. “Graphene Biointerfaces for Optical Stimulation of Cells.” Science Advances 4 (5): eaat0351.
    https://doi.org/10.1126/sciadv.aat0351.
    Research Journal.
  • Research Journal
    April 7, 2016. Samad Ahadian, Yuanshu Zhou, Shukuyo Yamada, Mehdi Estili, Xiaobin Liang, Ken Nakajima, Hitoshi Shiku, and Tomokazu Matsue. “Graphene Induces Spontaneous Cardiac Differentiation in Embryoid Bodies.” Nanoscale 8 (13): 7075–84.
    https://doi.org/10.1039/c5nr07059g.
    Research Journal.
  • Reference
    “Hollywood/Predictive Programming.” Wikispooks.
    https://wikispooks.com/wiki/Hollywood/Predictive_programming.
    Reference.
  • Research Journal Blog
    August 1, 2012. Rajni Singh. “Fungi as Builders For Nanomaterials.” Biotech Articles.
    https://www.biotecharticles.com/Nanotechnology-Article/Fungi-as-Builders-For-Nanomaterials-1545.html.
    Research Journal, Blog.

See also, on this site:

]]> FDA approves Comirnaty COVID-19 Vaccine https://pandemictimeline.com/2021/08/fda-approves-comirnaty-covid-19-vaccine/ Mon, 23 Aug 2021 00:00:00 +0000 https://pandemictimeline.com/?p=4453 There is a rumor going around that the approval is for the name change. After looking at the Approval Letter from the FDA’s Comirnaty and Pfizer-BioNTech COVID-19 Vaccine page, it does appear to be the licensing letter for the inoculation.  This is apparent in the terms used, which are different from those in an Emergency…

Read more →

]]>

There is a rumor going around that the approval is for the name change. After looking at the Approval Letter from the FDA’s Comirnaty and Pfizer-BioNTech COVID-19 Vaccine page, it does appear to be the licensing letter for the inoculation.  This is apparent in the terms used, which are different from those in an Emergency Use Authorization.  Compare the language used in the approval letter with those issued with the EUAs.  It looks like there are still some final details that are being worked out; otherwise, it appears that the Comirnaty inoculation is now fully approved for sale.  As of yet, the Comirnaty jab is not available in the US.  The Comirnaty/Pfizer-BioNTech Fact Sheet for Healthcare Providers Administering Vaccine clearly states that pre-authorization Pfizer-BioNTech vaccine and the Comirnaty vaccine are equivalent.  However, a recent judicial ruling claims that there is no legal equivalency, and they are not interchangeable.

  • Food & Drug Administration
    October 20, 2021. “Fact Sheet for Healthcare Providers Administering Vaccine [Pfizer-BioNTech].” US Food & Drug Administration. https://www.fda.gov/media/144413/download.
    Food & Drug Administration.
    This document has instructions for healthcare providers who are administering the vaccines.

However, another letter from August 23, 2021, admits that there are differences between the Pfizer-BioNTech vaccine and the Comirnaty vaccine, though they are not spelled out.

The licensed vaccine has the same formulation as the EUA-authorized vaccine and the products can be used interchangeably to provide the vaccination series without presenting any safety or effectiveness concerns. The products are legally distinct with certain differences that do not impact safety or effectiveness.

The FDA is saying that the products are legally distinct.  They are not the same.  A case can be made that if the recipient did not receive a jab that did came out of a vial with a Comirnaty label, they did not receive the approved vaccine.

The Approval Letter ends thus:

POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please contact the Regulatory Project Manager for this application.

So, if we have concerns, we have been invited to share them.

Meanwhile, the trials have NOT been completed.  Furthermore, the trial has already been unblinded and is thus no longer a randomized control trial.  The Phase III trial is not scheduled for completion until May 2, 2023.  In other words, Comirnaty was approved prior to completion of required trials.

Page 14 of CCCA report: Pfizer did not follow established protocols

I believe that Dr. Jane Ruby in the interview below has properly assessed the situation.  In discussing the proposed Comirnaty package insert, she said:

This document is so paltry, I have to tell you, in my estimation, the FDA itself has violated its own federal [regulations].  In that situation, to me, this is an illegal approval, and the FDA is committing crimes.

— Dr. Jane Ruby

Compare the proposed Comirnaty package insert to inserts for other products, and the differences in quality of content become obvious.

Dr. Ruby then goes on to list some 20 alleged crimes that were committed just in the package insert.

Dr. Ruby offers a ray of hope: 50% of those inoculated received a placebo.

The ingredients list is due on September 7.

They had to ignore a whole lot to approve the inoculation.  This is not about health.

Sources:

Related:

See also, on this site:

]]>